A Preliminary Study of Dopamine Transporter Binding in Bipolar and Unipolar Depressed Patients and Healthy Controls

Abstract

Objective: We examined striatal dopamine transporter (DAT) binding in bipolar and unipolar depressed patients and compared these values to those obtained from healthy control subjects using the selective DAT radioligand [^99mTc]TRODAT-1 and single photon emission computed tomography imaging. We hypothesized that DAT levels might be higher in bipolar versus unipolar patients. Methods: [^99mTc]TRODAT-1 scans were acquired from 5 bipolar and 10 unipolar patients and from 46 healthy controls. Distribution volume ratio (DVR) of [^99mTc]TRODAT-1 binding affinity was calculated for regions of interest in the striatum. Results: Bipolar patients had greater DVR values compared to controls in the right posterior putamen (p = 0.001) and in the left caudate region (p = 0.007). Bipolar patients had modestly lower DAT binding in all brain regions examined, and a significantly lower DVR in the right caudate region compared to unipolar patients (p = 0.05). Conclusion: These data suggest that striatal DAT density may be increased in bipolar and unipolar depressed patients compared to controls, and that bipolar and unipolar depressed patients may have a different pattern of striatal DAT binding.

© 2007 S. Karger AG, Basel

---

Article / Publication Details

---

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.